# US 8,541,167 B2 · Methods and compositions for vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,167 B2
- Document ID: US8541167B2
- Status: Granted
- Kind: B2
- Application number: 11/569,963
- Filed: 2005-05-26
- Published: 2009-04-02
- Granted: 2013-09-24
- Earliest claimed: 2004-06-03
- Assignees: Saint Louis University
- Applicants: Robert Mark Buller
- Inventors: Robert Mark Buller
- Web page: https://patentgrep.com/patent/US8541167B2

## CPC

- A61K 39/275: Poxviridae, e.g. avipoxvirus
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 39/12: Viral antigens
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2710/24034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides kits, methods and compositions of matter which improve the safety of vaccination. By combining the administration of antiviral drugs, particularly ester derivatives of cidofovir, with the administration of viral vaccines, particularly the variola vaccine DryVax, side effects of the vaccine are diminished without significantly affecting the effectiveness of the vaccine.

## Claims

### Claim 1

A method of vaccinating or immunizing an individual against smallpox virus comprising the steps of administering to an individual a nucleoside analog or a derivative of a nucleoside analog antiviral agent that is cidofovir or an analog of cidofovir and a vaccine or immunizing agent wherein the vaccine or immunizing agent elicits an immune response in the individual and the vaccine or immunizing agent is a live, attenuated smallpox vaccine, wherein the antiviral agent and the vaccine or immunizing agent are co-administered.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antiviral agent is selected from the group consisting of HDP-CDV and ODE-CDV.

### Claim 3

A composition comprising a nucleoside analog or a derivative of a nucleoside analog antiviral agent that is cidofovir or an analog of cidofovir and a vaccine or immunizing agent against smallpox virus, wherein the vaccine or immunizing agent elicits an immune response in an individual and the vaccine or immunizing agent is a live, attenuated smallpox virus.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the immune response is selected from the group consisting of a humoral response, a cellular response, protective immunity, production of epitope specific antibody, and production of epitope specific T-cell.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the antiviral agent is selected from the group consisting of: HDP-CDV and ODE-CDV.